Nolasiban

Summary

Nolasiban (CHEMBL1254025) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including infertility disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 338.4 Da · C20H22N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1254025
Name	Nolasiban
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	52947354
Molecular formula	C20H22N2O3
Molecular weight	338.4
InChIKey	OLUJSZLBWZWGJT-HGBKYHTQSA-N

SMILES: CC1=CC=CC=C1C2=CC=C(C=C2)C(=O)N3C/C(=N\OC)/C[C@H]3CO

IUPAC name: [(2S,4Z)-2-(hydroxymethyl)-4-methoxyiminopyrrolidin-1-yl]-[4-(2-methylphenyl)phenyl]methanone

Also known as: Erlosiban, Nolasiban, OBE-001, Obe001, NOLASIBAN

Patent coverage: 19 distinct patent families (100 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 79 (79%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Vasopressin V1a receptor, Oxytocin receptor, Oxytocin receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 3 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OXTR	7.02	Ki	95	nM	CHEMBL_ACT_3465639
P70536	6.68	Ki	210	nM	CHEMBL_ACT_3465640
AVPR1A	6.48	Ki	330	nM	CHEMBL_ACT_3465641

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03081208	PHASE3	COMPLETED	Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI
NCT03758885	PHASE3	COMPLETED	Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF
NCT02326142	PHASE2	TERMINATED	A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).